Covered recipient · General Payments record
JOSEPH JAMES ROCHE
Allopathic & Osteopathic Physicians Dermatology
General Payments · PY2018–2024
$2,174.27
- Reported across 76 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $588.19 | 34 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| ABBVIE INC. | $270.66 | 20 |
| UCB, Inc. | $138.64 | 5 |
| Lilly USA, LLC | $42.59 | 2 |
| NOVARTIS PHARMACEUTICALS CORPORATION | $32.81 | 2 |
| Regeneron Healthcare Solutions, Inc. | $30.30 | 1 |
| Dermavant Sciences, Inc. | $23.69 | 1 |
| E.R. Squibb & Sons, L.L.C. | $18.58 | 1 |
| SUN PHARMACEUTICAL INDUSTRIES INC. | $17.40 | 1 |
| Galderma Laboratories, L.P. | $13.52 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (34)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| ABBVIE INC. | $5.58 | 01/31/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1105961880 | CMS |
| ABBVIE INC. | $8.23 | 01/31/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1105961882 | CMS |
| ABBVIE INC. | $32.21 | 04/03/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1105961884 | CMS |
| ABBVIE INC. | $10.31 | 05/01/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1105961886 | CMS |
| ABBVIE INC. | $5.37 | 05/01/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1105961888 | CMS |
| ABBVIE INC. | $19.49 | 05/30/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1105961890 | CMS |
| ABBVIE INC. | $12.27 | 05/30/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1105961892 | CMS |
| ABBVIE INC. | $11.38 | 07/02/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1105961894 | CMS |
| ABBVIE INC. | $25.72 | 08/19/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1105961896 | CMS |
| ABBVIE INC. | $14.36 | 08/28/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1105961898 | CMS |
| ABBVIE INC. | $6.12 | 09/10/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1105961900 | CMS |
| ABBVIE INC. | $13.69 | 09/11/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1105961902 | CMS |
| ABBVIE INC. | $13.96 | 09/26/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1105961904 | CMS |
| ABBVIE INC. | $12.72 | 10/02/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1105961906 | CMS |
| ABBVIE INC. | $27.18 | 10/10/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1105961908 | CMS |
| ABBVIE INC. | $15.34 | 10/14/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1105961910 | CMS |
| ABBVIE INC. | $12.60 | 10/22/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1105961912 | CMS |
| ABBVIE INC. | $4.45 | 11/19/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1105961914 | CMS |
| ABBVIE INC. | $7.79 | 11/26/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1105961916 | CMS |
| ABBVIE INC. | $11.89 | 12/02/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1105961918 | CMS |
| Dermavant Sciences, Inc. | $23.69 | 09/19/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1127924718 | CMS |
| E.R. Squibb & Sons, L.L.C. | $18.58 | 01/11/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1101311191 | CMS |
| Galderma Laboratories, L.P. | $13.52 | 11/06/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1145324319 | CMS |
| Lilly USA, LLC | $21.73 | 11/13/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135084652 | CMS |
| Lilly USA, LLC | $20.86 | 12/03/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135093631 | CMS |
| Novartis Pharmaceuticals Corporation | $15.09 | 08/21/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1087267683 | CMS |
| Novartis Pharmaceuticals Corporation | $17.72 | 10/09/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1087267691 | CMS |
| Regeneron Healthcare Solutions, Inc. | $30.30 | 05/23/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1114148067 | CMS |
| SUN PHARMACEUTICAL INDUSTRIES INC. | $17.40 | 09/17/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1152164310 | CMS |
| UCB, Inc. | $26.38 | 02/07/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1143326471 | CMS |
| UCB, Inc. | $39.26 | 02/22/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1143326475 | CMS |
| UCB, Inc. | $13.44 | 05/22/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1143326479 | CMS |
| UCB, Inc. | $12.49 | 08/07/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1143326483 | CMS |
| UCB, Inc. | $47.07 | 12/17/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1143326488 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2018, 2019, 2020, 2021, 2022, 2023, 2024
- Source files
- Dataset page · Bulk file · PY2018 , PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.